Cargando…
Activation of M(1) and M(4) muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia
Alzheimer’s disease (AD) and schizophrenia (SZ) are neurological disorders with overlapping symptomatology, including both cognitive deficits and behavioral disturbances. Current clinical treatments for both disorders have limited efficacy accompanied by dose-limiting side effects, and ultimately fa...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913542/ https://www.ncbi.nlm.nih.gov/pubmed/24511233 http://dx.doi.org/10.2147/NDT.S55104 |
_version_ | 1782302242488975360 |
---|---|
author | Foster, Daniel J Choi, Derrick L Conn, P Jeffrey Rook, Jerri M |
author_facet | Foster, Daniel J Choi, Derrick L Conn, P Jeffrey Rook, Jerri M |
author_sort | Foster, Daniel J |
collection | PubMed |
description | Alzheimer’s disease (AD) and schizophrenia (SZ) are neurological disorders with overlapping symptomatology, including both cognitive deficits and behavioral disturbances. Current clinical treatments for both disorders have limited efficacy accompanied by dose-limiting side effects, and ultimately fail to adequately address the broad range of symptoms observed. Novel therapeutic options for AD and SZ are needed to better manage the spectrum of symptoms with reduced adverse-effect liability. Substantial evidence suggests that activation of muscarinic acetylcholine receptors (mAChRs) has the potential to treat both cognitive and psychosis-related symptoms associated with numerous central nervous system (CNS) disorders. However, use of nonselective modulators of mAChRs is hampered by dose-limiting peripheral side effects that limit their clinical utility. In order to maintain the clinical efficacy without the adverse-effect liability, efforts have been focused on the discovery of compounds that selectively modulate the centrally located M(1) and M(4) mAChR subtypes. Previous drug discovery attempts have been thwarted by the highly conserved nature of the acetylcholine site across mAChR subtypes. However, current efforts by our laboratory and others have now focused on modulators that bind to allosteric sites on mAChRs, allowing these compounds to display unprecedented subtype selectivity. Over the past couple of decades, the discovery of small molecules capable of selectively targeting the M(1) or M(4) mAChR subtypes has allowed researchers to elucidate the roles of these receptors in regulating cognitive and behavioral disturbances in preclinical animal models. Here, we provide an overview of these promising preclinical and clinical studies, which suggest that M(1)- and M(4)-selective modulators represent viable novel targets with the potential to successfully address a broad range of symptoms observed in patients with AD and SZ. |
format | Online Article Text |
id | pubmed-3913542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-39135422014-02-07 Activation of M(1) and M(4) muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia Foster, Daniel J Choi, Derrick L Conn, P Jeffrey Rook, Jerri M Neuropsychiatr Dis Treat Review Alzheimer’s disease (AD) and schizophrenia (SZ) are neurological disorders with overlapping symptomatology, including both cognitive deficits and behavioral disturbances. Current clinical treatments for both disorders have limited efficacy accompanied by dose-limiting side effects, and ultimately fail to adequately address the broad range of symptoms observed. Novel therapeutic options for AD and SZ are needed to better manage the spectrum of symptoms with reduced adverse-effect liability. Substantial evidence suggests that activation of muscarinic acetylcholine receptors (mAChRs) has the potential to treat both cognitive and psychosis-related symptoms associated with numerous central nervous system (CNS) disorders. However, use of nonselective modulators of mAChRs is hampered by dose-limiting peripheral side effects that limit their clinical utility. In order to maintain the clinical efficacy without the adverse-effect liability, efforts have been focused on the discovery of compounds that selectively modulate the centrally located M(1) and M(4) mAChR subtypes. Previous drug discovery attempts have been thwarted by the highly conserved nature of the acetylcholine site across mAChR subtypes. However, current efforts by our laboratory and others have now focused on modulators that bind to allosteric sites on mAChRs, allowing these compounds to display unprecedented subtype selectivity. Over the past couple of decades, the discovery of small molecules capable of selectively targeting the M(1) or M(4) mAChR subtypes has allowed researchers to elucidate the roles of these receptors in regulating cognitive and behavioral disturbances in preclinical animal models. Here, we provide an overview of these promising preclinical and clinical studies, which suggest that M(1)- and M(4)-selective modulators represent viable novel targets with the potential to successfully address a broad range of symptoms observed in patients with AD and SZ. Dove Medical Press 2014-01-28 /pmc/articles/PMC3913542/ /pubmed/24511233 http://dx.doi.org/10.2147/NDT.S55104 Text en © 2014 Foster et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Foster, Daniel J Choi, Derrick L Conn, P Jeffrey Rook, Jerri M Activation of M(1) and M(4) muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia |
title | Activation of M(1) and M(4) muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia |
title_full | Activation of M(1) and M(4) muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia |
title_fullStr | Activation of M(1) and M(4) muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia |
title_full_unstemmed | Activation of M(1) and M(4) muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia |
title_short | Activation of M(1) and M(4) muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia |
title_sort | activation of m(1) and m(4) muscarinic receptors as potential treatments for alzheimer’s disease and schizophrenia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913542/ https://www.ncbi.nlm.nih.gov/pubmed/24511233 http://dx.doi.org/10.2147/NDT.S55104 |
work_keys_str_mv | AT fosterdanielj activationofm1andm4muscarinicreceptorsaspotentialtreatmentsforalzheimersdiseaseandschizophrenia AT choiderrickl activationofm1andm4muscarinicreceptorsaspotentialtreatmentsforalzheimersdiseaseandschizophrenia AT connpjeffrey activationofm1andm4muscarinicreceptorsaspotentialtreatmentsforalzheimersdiseaseandschizophrenia AT rookjerrim activationofm1andm4muscarinicreceptorsaspotentialtreatmentsforalzheimersdiseaseandschizophrenia |